Abstract
Advanced glycation end products (AGEs) have been reported to contribute to aging and cardiovascular complications. In the present study, the immunoreactivity of AGEs in human serum samples of healthy older subjects (n = 31), senile diabetic patients without cardiovascular complications (n = 33), senile diabetic patients with cardiovascular complications (n = 32), senile non-diabetic patients with cardiovascular complications (n = 30) ,and healthy young subjects (n = 31) were investigated. The patients were selected on clinical grounds from the National Institute of Cardiovascular Disease, Karachi and the Jinnah Postgraduate Medical Centre, Karachi, Pakistan. Fasting blood glucose, HbA1C and serum fructosamine levels were significantly (P < 0.001) increased in senile diabetic patients with and without cardiovascular complications as compared to non-diabetic senile patients with cardiovascular complications and healthy older subjects. Additionally, serum AGEs were found to be significantly (P < 0.001) increased in senile diabetic patients with cardiovascular complications and senile non-diabetic patients with cardiovascular complications, followed by diabetic patients without cardiovascular complications as compared to healthy older subjects and young control subjects. However, no significant difference was found in the senile diabetic patients without cardiovascular complications and senile non-diabetic patients with cardiovascular complications. In contrast to all four senile groups, serum AGEs were significantly (P < 0.001) lower in young control subjects. The AGEs distribution in the senile groups corroborates the hypothesis that the advanced glycation process might play a role in the development of cardiovascular complications, which are more severe in diabetic patients compared with non-diabetic patients with cardiovascular complications.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ahmed N (2005) Advanced glycation endproducts-role in pathology of diabetic complications. Diabetes Res Clin Pract 67:3–21 doi:10.1016/j.diabres.2004.09.004
Basta G, Del Turco S, De Caterina R (2004) Advanced glycation end products: implications for accelerated atherosclerosis in diabetes. Recent Prog Med 95:67–80
Baynes JW, Thorpe SR (2000) Glycoxidation and lipoxidation in atherogenesis. Free Radic Biol Med 28:1708–1716 doi:10.1016/S0891-5849(00)00228-8
Bierhaus A, Chevion S, Chevion M, Hofmann M, Quehenberger P, Illmer T et al (1997) Advanced glycation end product-induced activation of NF-kB is suppressed by a-lipoic acid in cultured endothelial cells. Diabetes 46:1481–1490 doi:10.2337/diabetes.46.9.1481
Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414:813–820 doi:10.1038/414813a
Chuyen NV (2006) Toxicity of the AGEs generated from the Maillard reaction: on the relationship of food-AGEs and biological-AGEs. Mol Nutr Food Res 50:1140–1149 doi:10.1002/mnfr.200600144
Dyer DG, Blackledge JA, Thorpe SR, Baynes JW (1991) Formation of pentosidine during nonenzymatic browning of protein by glucose: identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo. J Biol Chem 266:11654–11660
Gabir MM, Roumain J, Hanson RL, Bennett PH, Dabelea D, Knowler WC et al (2000) The 1997 American Diabetes Association and 1999 World Health Organization criteria for hyperglycemia in the diagnosis and prediction of diabetes. Diabetes Care 23:1108–1112 doi:10.2337/diacare.23.8.1108
Kanauchi M, Tsujimoto N, Hashimoto T (2001) Advanced glycation end products in nondiabetic patients with coronary artery disease. Diabetes Care 24:1620–1623 doi:10.2337/diacare.24.9.1620
Khaw K, Wareham N, Luben R, Bingham S, Oakes S, Welch A et al (2001) Glycated hemoglobin, diabetes and mortality in men in Norfolk Cohort of European prospective investigation of cancer and nutrition (EPIC-Norfolk). BMJ 322:1–6 doi:10.1136/bmj.322.7277.15
Lyons TJ (1993) Glycation and oxidation: a role in the pathogenesis of atherosclerosis. Am J Cardiol 71:26B–31B doi:10.1016/0002-9149(93)90142-Y
Miyata T, Ishikawa N, van Ypersele de Strihou C (2003) Carbonyl stress and diabetic complications. Clin Chem Lab Med 41:1150–1158 doi:10.1515/CCLM.2003.178
Ono Y, Aoki S, Ohnishi K, Yasuda T, Kawano K, Tsukada Y (1998) Increased serum levels of advanced glycation end-products and diabetic complications. Diabetes Res Clin Pract 41:131–137 doi:10.1016/S0168-8227(98)00074-6
Peppa M, Uribarri J, Vlassara H (2004) The role of advanced glycation end products in the development of atherosclerosis. Curr Diabetes Rep 4:31–36 doi:10.1007/s11892-004-0008-6
Saleheen D, Frossard P (2004) CAD risk factors and acute myocardial infarction in Pakistan. Acta Cardiol 59:417–424 doi:10.2143/AC.59.4.2005208
Schleicher E, Friess U (2007) Oxidative stress, AGE, and atherosclerosis. Kidney Int Suppl 106:S17–S26 doi:10.1038/sj.ki.5002382
Schmidt AM, Vianna M, Gerlach M, Brett J, Ryan J, Kao J et al (1992) Isolation and characterization of binding proteins for advanced glycosylation end products from lung tissue which are present on the endothelial cell surface. J Biol Chem 267:14987–14997
Shera S (1998) Prevalence and prevention. Diabetes Dig 12:7–8
Sims TJ, Rasmussen LM, Oxlund H, Bailey AJ (1996) The role of glycation cross-links in diabetic vascular stiffening. Diabetologia 39:964–951 doi:10.1007/BF00403914
Soldatos G, Cooper ME (2006) Advanced glycation end products and vascular structure and function. Curr Hypertens Rep 8:472–478 doi:10.1007/s11906-006-0025-8
Ulrich P, Cerami A (2001) Protein glycation, diabetes, and aging. Recent Prog Horm Res 56:1–21 doi:10.1210/rp.56.1.1
Uribarri J, Cai W, Peppa M, Goodman S, Ferrucci L, Striker G et al (2007) Circulating glycotoxins and dietary advanced glycation endproducts: two links to inflammatory response, oxidative stress and aging. J Gerontol A Biol Sci Med Sci 62:427–433
Valeri C, Pozzilli P, Leslie D (2004) Glucose control in diabetes. Diabetes Metab Res Rev 20:S1–S8 doi:10.1002/dmrr.512
Veiraiah A (2005) Hyperglycemia, lipoprotein glycation, and vascular disease. Angiology 56:431–438 doi:10.1177/000331970505600411
Vlassara H, Palace MR (2003) Glycoxidation: the menace of diabetes and aging. Mt Sinai J Med 70:232–241
Wright E Jr, Scism-Bacon JL, Glass LC (2006) Oxidative stress in type 2 diabetes: the role of fasting and postprandial glycaemia. Int J Clin Pract 60:308–314 doi:10.1111/j.1368-5031.2006.00825.x
Xanthis A, Hatzitolios A, Koliakos G, Tatola V (2007) Advanced glycosylation end products and nutrition-a possible relation with diabetic atherosclerosis and how to prevent it. J Food Sci 72:125–129 doi:10.1111/j.1750-3841.2007.00508.x
Yamagishi S, Imaizumi T (2005) Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des 11:2279–2299 doi:10.2174/1381612054367300
Yamagishi S, Matsui T, Ueda S, Nakamura K, Imaizumi T (2007) Advanced glycation end products (AGEs) and cardiovascular disease (CVD) in diabetes. Cardiovasc Hematol Agents Med Chem 5:236–240
Yan SF, Yan SD, Herold K, Ramsamy R, Schmidt AM (2006) Receptor for advanced glycation end products and the cardiovascular complications of diabetes and beyond: lessons from AGEing. Endocrinol Metab Clin North Am 35:511–524 doi:10.1016/j.ecl.2006.06.003
Acknowledgment
This work was financially supported by Pakistan Science Foundation grant.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Gul, A., Rahman, M.A., Salim, A. et al. Advanced glycation end-products in senile diabetic and non-diabetic patients with cardiovascular complications. AGE 30, 303–309 (2008). https://doi.org/10.1007/s11357-008-9072-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11357-008-9072-1